Increased Blood Concentration of IgG Degradation Products in Prostate Cancer.

Autor: Goufman IE; Research Institute of Human Morphology, Moscow, Russia. eugene_goufman@mail.ru., Yakovlev VN; Angiogen Company, Moscow, Russia., Tikhonova NB; Research Institute of Human Morphology, Moscow, Russia., Matevosyan KS; Research Institute of Human Morphology, Moscow, Russia., Boltovskaya MN; Research Institute of Human Morphology, Moscow, Russia., Aisina RB; M. V. Lomonosov Moscow State University, Moscow, Russia., Mukhametova LI; M. V. Lomonosov Moscow State University, Moscow, Russia., Gershkovich KB; N. M. Emanuel Institute for Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
Jazyk: angličtina
Zdroj: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2019 Mar; Vol. 166 (5), pp. 651-655. Date of Electronic Publication: 2019 Mar 23.
DOI: 10.1007/s10517-019-04411-5
Abstrakt: For elucidation of the mechanisms of IgG binding with human plasminogen in prostate cancer patients, we propose an original ELISA on polystyrene plates with immobilized heavy and light plasminogen chains. The level of IgG bound to plasminogen heavy chain in the serum of prostate cancer patients significantly exceeded that in healthy volunteers. IgG treated with plasmin more actively (by more than 2 times) bound plasminogen heavy chain than intact IgG. These findings indicate the involvement of lysine-binding sites of plasminogen heavy chain in the interaction with the C-terminal lysine of IgG and their fragments. ROC analysis of ELISA data showed significant differences between serum samples from patients with prostate cancer and benign prostatic hyperplasia. It is hypothesized that IgG in the tumor region undergo proteolysis and their products appear in the circulation.
Databáze: MEDLINE
Externí odkaz: